0000000001278465

AUTHOR

Andrea Magistro

showing 6 related works from this author

Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome

2014

ObjectiveOn the basis of the known diabetes risk in polycystic ovary syndrome (PCOS), recent guidelines of the Endocrine Society recommend the use of an oral glucose tolerance test (OGTT) to screen for impaired glucose tolerance (IGT) and type 2 diabetes (T2DM) in all women with PCOS. However, given the high prevalence of PCOS, OGTT would have a high cost–benefit ratio. In this study, we identified, through a receiver operating characteristic analysis, simple predictive markers of the composite endpoint (impaired fasting glucose (IFG) or IGT or IFG+IGT or T2DM) in women with PCOS according to the Rotterdam criteria.DesignWe conducted a cross-sectional study of 241 women with PCOS in a unive…

AdultBlood Glucosemedicine.medical_specialtyDiabetes riskWaistendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismType 2 diabetesIntra-Abdominal FatSettore MED/13 - EndocrinologiaImpaired glucose toleranceYoung AdultInsulin resistanceEndocrinologyAdiposity; Adolescent; Adult; Biological Markers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Humans; Intra-Abdominal Fat; Polycystic Ovary Syndrome; Risk Factors; Young Adult; Endocrinology; Endocrinology Diabetes and Metabolism; Medicine (all)Risk FactorsInternal medicineDiabetes mellitusmedicineHumansAdiposityCross-Sectional Studiebusiness.industryRisk FactorMedicine (all)nutritional and metabolic diseasesGeneral MedicineImpaired fasting glucosemedicine.diseasePolycystic ovaryCross-Sectional StudiesEndocrinologyDiabetes Mellitus Type 2Biological MarkerFemalebusinessBiomarkersHumanPolycystic Ovary Syndrome
researchProduct

La FR.E.M.S. (FRequency modulated ElectroMagnetic neural Stimulation): una nuova prospettiva terapeutica per la neuropatia diabetica dolorosa degli a…

2009

The FR.E.M.S. therapy represents an useful therapeutic remedy for the symptomatic management of the diabetic patients with a painful sensitive neuropathy.

FR.E.M.S. therapy painful diabetic neuropathy.Settore MED/13 - Endocrinologia
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Marcatori di rischio diabetologico nella Sindrome dell’ovaio policistico (PCOS).

2014

PCOS
researchProduct

Oligomenorrhea in PCOS is characterized by a high visceral adiposity index (VAI): a likely condition of cardiometabolic risk.

2011

Visceral adiposity index
researchProduct

Poor diagnostic value of the euglycemic-hyperinsulinemic clamp in the clinical assessment of insulin resistant women with PCOS.

2013

Insulin resistance (IR) per se and/or the ensuing compensatory hyperinsulinism, have been always considered as a key point in the pathogenesis of PCOS. Aim of our study was to evaluate which of these two aspects plays a key role in the pathogenesis of PCOS. Using a cross-sectional study design, 15 PCOS (Rotterdam criteria) and 16 age/BMI-matched control women (with suspect of IR) underwent clinical measures of IR after a 3-month withdrawal of insulin sensitizers and oral contraceptive pills. In an academic clinic setting, average glucose infusion rate (M-value) (during an euglycaemic–hyperinsulinaemic clamp), AUCinsulin and AUCglucose (during an Oral Glucose tolerance Test), HOMA-IR, ISI-Ma…

PCOS
researchProduct